2021
Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites
Yan K, Hung A, Parmer C, Yang H, Jain D, Lim B, Goodman AL, Garcia‐Tsao G. Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites. Hepatology Communications 2021, 5: 1507-1517. PMID: 34510838, PMCID: PMC8435275, DOI: 10.1002/hep4.1740.Peer-Reviewed Original ResearchHigher serum albuminBacterial translocationObeticholic acidEnd of studyAspartate aminotransferaseLymph nodesIntestinal microbiomeIntestinal contentsSemisynthetic bile acidMesenteric lymph nodesEnd of treatmentCarbon tetrachloride inhalationExtra-intestinal sitesLower aspartate aminotransferaseFurther decompensationLiver injuryLiver functionPolymerase chain reactionExperimental cirrhosisPathogenic bacteriaCirrhosisHepatocyte deathDay 1Bile acidsPlacebo
2019
Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
Garcia‐Tsao G, Fuchs M, Shiffman M, Borg BB, Pyrsopoulos N, Shetty K, Gallegos‐Orozco J, Reddy KR, Feyssa E, Chan JL, Yamashita M, Robinson JM, Spada AP, Hagerty DT, Bosch J. Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology 2019, 69: 717-728. PMID: 30063802, PMCID: PMC6587783, DOI: 10.1002/hep.30199.Peer-Reviewed Original ResearchConceptsSevere portal hypertensionPortal hypertensionAlanine aminotransferaseCompensated cirrhosisEnd-stage liver disease (MELD) scoreAspartate aminotransferaseAST/alanine aminotransferaseChild class ALiver Disease scoreOpen-label studyNonserious adverse eventsPortal venous inflowAnti-inflammatory effectsHepatitis C virusSplanchnic vasodilationAdverse eventsHVPG measurementIntrahepatic inflammationPortal pressureBlood pressureCirrhosis etiologyMedian ageNonalcoholic steatohepatitisVenous inflowSignificant changes